Search This Blog

Wednesday, August 27, 2025

Neuphoria Therapeutics’s BNC210: Buy Rating Affirmed Ahead of Pivotal Phase 3 AFFIRM-1 Trial

 Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Neuphoria Therapeutics. The associated price target is $21.00.

https://www.tipranks.com/news/ratings/neuphoria-therapeuticss-bnc210-buy-rating-affirmed-ahead-of-pivotal-phase-3-affirm-1-trial-ratings

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)